Research

Medical Sciences

Title :	SREBP inhibitors as novel therapeutics for non-alcoholic fatty liver disease: Insights on CRISPER-Cas9 inhibition of SREBPs targeting activated hepatic stellate cells
Area of research :	Life Sciences & Biotechnology, Medical Sciences
Focus area :	Non-alcoholic fatty liver disease
Principal Investigator :	Dr P. Madan Kumar, Scientist, CSIR-Central Food Technological Research Institute (CFTRI), Karnataka
Timeline Start Year :	2020
Timeline End Year :	2023
Contact info :	director@cftri.res.in

Details

Executive Summary :

Objective: Evaluating the role of SREBPs and SREBP inhibition in experimental model of NAFLD using ApoE deficient mice. Histological and immunohistochemical analysis of the fatty liver. Determining the effect of SREBP inhibition in HSCs and food bioactive binding induced changes in SREBP stability. Determining the initial toxicity, nutridynamics and nutrikinetics of food SREBP inhibitors. Determining the initial toxicity, nutridynamics and nutrikinetics of food SREBP inhibitors. Determining the effect of SREBP inhibition in HSCs and food bioactive binding induced changes in SREBP stability. Histological and immunohistochemical analysis of the fatty liver. Evaluating the role of SREBPs and SREBP inhibition in experimental model of NAFLD using ApoE deficient mice.

Organizations involved

Implementing Agency :	CSIR-Central Food Technological Research Institute (CFTRI), Karnataka CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad
Funding Agency :	Council of Scientific and Industrial Research (CSIR), Government of India
Source (more info) :	https://csirprojects.anusandhan.net/